ストックスクリーナーアプリを入手
65.28
1.89%
-1.26
前日終値:
$66.54
開ける：
$66.04
24時間の取引高:
1.05M
Relative Volume:
0.57
時価総額：
$6.15B
収益：
$536.20M
当期純損益:
$-45.64M
株価収益率:
-122.06
EPS:
-0.5348
ネットキャッシュフロー:
$-28.94M
1週間 パフォーマンス:
-0.59%
1か月 パフォーマンス:
+16.53%
6か月 パフォーマンス:
+131.65%
1年 パフォーマンス:
+208.65%
1日の値動き範囲:
$65.04
$67.11
1週間の範囲:
$65.04
$68.03
52週間の値動き範囲:
$20.84
$68.03
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
65.28 | 6.08B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com - Investing.com South Africa
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations - Sahm
Travere Therapeutics (TVTX) director sells 10K shares under 10b5-1 plan - Stock Titan
Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX) - Seeking Alpha
US High Growth Tech Stocks To Watch In August 2026 - Sahm
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics (NASDAQ: TVTX) director plans 5,000-share sale tied to stock options - Stock Titan
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline - Yahoo Finance
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Travere Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Travere Therapeutics (TVTX) Advances 3.12% to $64.08, Approaching Key Resistance at $67.28Dark Pool Sentiment - vinanet.vn
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript - AOL.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A - Stock Titan
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net LossHas The Bull Case Changed? - webull.com
(TVTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $74.62, Implies 20% Upside - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Bank of America Corp (TVTX) discloses 5.8% beneficial stake in Travere Therapeutics - Stock Titan
What is HC Wainwright's Estimate for TVTX Q3 Earnings? - marketbeat.com
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP - MarketBeat
Travere Therapeutics grants 38,940 inducement RSUs to 12 new employees - Bitget
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TVTX Maintained by Evercore ISI Group -- Price Target Raised to $78 - GuruFocus
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
California State Teachers Retirement System Increases Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Hennion & Walsh Asset Management Inc. Raises Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports First Quarter 2026 Financial Results - The National Law Review
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
State Street Corporation (TVTX) discloses 4.6% beneficial stake in Travere - Stock Titan
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Travere Therapeutics Inc (TVTX) Stock News Today - TradingKey
Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss - Yahoo Finance
Travere Therapeutics (TVTX) On Q2 Results And FILSPARI Hopes As Fair Value Stays In View - Yahoo Finance Singapore
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $70 - GuruFocus
Travere Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-08-06 - Seeking Alpha
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On - webull.com
TVTX Maintained by Wedbush -- Price Target Raised to $75 - GuruFocus
FMR LLC (TVTX) discloses 7.1M Travere Therapeutics shares under amended 13G - stocktitan.net
Travere Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX) - Seeking Alpha
Can Travere Therapeutics (TVTX) Be A Bargain After Its Q2 Surge? - Yahoo Finance
Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Acquired by Sei Investments Co. - MarketBeat
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LYONS GARY A | Director |
Aug 18 '26 |
Option Exercise |
17.44 |
5,000 |
87,200 |
66,500 |
| LYONS GARY A | Director |
Aug 18 '26 |
Sale |
63.37 |
5,000 |
316,860 |
61,500 |
| LYONS GARY A | Director |
Aug 17 '26 |
Sale |
63.20 |
5,000 |
315,986 |
61,500 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):